CyberKnife Stereotactic Radiotherapy for Patients with Malignant Glioma

Abstract

Objective: The CyberKnife is a new frameless image-guided radiosurgical modality. The authors report on their experience using the CyberKnife in 25 patients with malignant gliomas. Methods: Twenty-five patients with histologically proven malignant gliomas (18 glioblastoma: GB, 7 anaplastic astrocytoma: AA) were treated with the CyberKnife at Konan St. Hill Hospital between June 1998 and November 2002. CyberKnife therapy was performed on 44 lesions (31 GB lesions, 13 AA lesions) in the 25 patients. The median target volume was 19.1 mL (range: 0.3 - 90.2). The median prescribed dose was 20.3 Gy (range: 13.9 - 26.4). Patient-, tumor-, and treatment-related variables were analyzed by univariate analysis, and survival curves were generated by the Kaplan-Meier product limit. Results: In the 18GB patients, the median survival after diagnosis was 20.7 months (82.6 weeks) with a mean follow-up of 85.7 weeks. Of the 7 AA patients, 6 were alive at the time of analysis with follow-up periods ranging from 11.4 to 52.8 months. Patients younger than 70 years had a median survival after diagnosis of 37.1 months, compared to 12.4 months for older patients (p = 0.003). Similarly, patients with well-controlled lesions had a median survival after diagnosis of 39.8 months compared to 16.0 months for those with uncontrolled lesions (p = 0.031). Late delayed radiation necrosis was seen in 1 GB patient. No other patient suffered acute or delayed neurological morbidity after CyberKnife therapy. Conclusion: This is the first report of CyberKnife stereotactic radiotherapy applied to the treatment of malignant gliomas. The frameless and painless CyberKnife stereotactic radiotherapy has the potential to be as useful for treatment of malignant glioma as other radiosurgical modalities.

CyberKnife - malignant glioma - stereotactic radiotherapy - fractionated radiosurgery

References

• 1 Kondziolka D, Flickinger J C, Bissonette D J, Bozik M, Lunsford L D. Survival benefit of stereotactic radiosurgery for patients with malignant glial neoplasms.  Neurosurgery. 1997;  41 776-785
• 2 Larson D A, Prados M, Lamborn K R, Smith V, Sneed P K, Chang S, Nicholas K M, Wara W M, Devriendt D, Kunwar S, Berger M, McDermott M W. Phase II study of high central dose gamma knife radiosurgery and marimastat in patients with recurrent malignant glioma.  Int J Radiat Oncol Biol Phys. 2002;  54 1397-1404
• 3 Masciopinto J E, Levin A B, Mehta M P, Rhode B S. Stereotactic radiosurgery for glioblastoma: a final report of 31 patients.  J Neurosurg. 1995;  82 530-535
• 4 Nwokedi E C, DiBiase S J, Jabbour S, Herman J, Amin P, Chin L S. Gamma knife stereotactic radiosurgery for patients with glioblastoma multiforme.  Neurosurgery. 2002;  50 41-47
• 5 Shrieve D C, Alexander E, Black P M, Wen P Y, Fine H A, Kooy H M, Loeffler J S. Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome.  J Neurosurg. 1999;  90 72-77
• 6 Adler J R, Chang S D, Murphy M J, Doty J, Geris P, Hancock S L. The Cyberknife: a frameless robotic system for radiosurgery.  Stereotact Funct Neurosurg. 1997;  69 124-128
• 7 Chang S D, Adler J R. Robotic and radiosurgery - the cyberknife.  Stereotact Funct Neurosurg. 2001;  76 204-208
• 8 Chang S D, Murphy M, Geis P, Martin D P, Hancock S L, Doty J R, Adler J R. Clinical experience with image-guided robotic radiosurgery (the Cyberknife) in the treatment of brain and spinal cord tumors.  Neurol Med Chir (Tokyo). 1998;  38 780-783
• 9 Fowler J F. The linear-quadratic formula and progress in fractionated radiotherapy.  Br J Radiol. 1989;  62 679-694
• 10 Fine H A, Dear K BG, Loeffler J S, Black P M, Canellos G P. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults.  Cancer. 1993;  71 2585-2597
• 11 Kelly P J, Hunt C. The limited value of cytoreductive surgery in elderly patients with malignant gliomas.  Neurosurgery. 1994;  34 62-67
• 12 Shapiro W R, Green S B, Burger P C, Mahaley M S, Selker R C, VanGilder J C, Robertson J T, Ransohoff J, Mealey J, Strike T A, Pistenmaa D A. Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001.  J Neurosurg. 1989;  71 1-9
• 13 Curran W J, Scott C B, Horton J, Nelson J S, Weinstein A S, Fischback A J, Chang C H, Rotman M, Asbell S O, Krisch R E, Nelson D F. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials.  J Natl Cancer Inst. 1993;  85 704-710
• 14 Laws E R, Parney I F, Huang W, Anderson F, Morris A M, Asher A, Lillehei K O, Bernstein M, Brem H, Sloan A, Berger M S, Chang S. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project.  J Neurosurg. 2003;  99 467-473
• 15 Chang S D, Main W, Martin D P, Gibbs I C, Heilbrun M P. An analysis of the accuracy of the CyberKnife: a robotic frameless stereotactic radiosurgical system.  Neurosurgery. 2003;  52 140-146
• 16 Shimamoto S, Inoue T, Shiomi H, Sumida I, Yamada Y, Tanaka E, Inoue T. CyberKnife stereotactic irradiation for metastatic brain tumors.  Radiat Med. 2002;  20 299-304
• 17 Stieber V W, Bourland J D, Tome W A, Mehta M P. Gentlemen (and ladies), choose your weapons: Gamma knife vs. linear accelerator radiosurgery.  Technol Cancer Res Treat. 2003;  2 79-86
• 18 Yu C, Jozsef G, Appuzzo M L, Petrovich Z. Dosimetric comparison of CyberKnife with other radiosurgical modalities for an ellipsoidal target.  Neurosurgery. 2003;  53 1155-1162
• 19 Wara W M, Bauman G S, Sneed P K, Larson D A, Karlsson U L. Brain, brain stem and cerebellum. In: Perez CA, Brady LW (eds). Principles and Practice of Radiation Oncology. 3rd edn. Philadelphia: Lippincott-Raven 1998: 777-828